Ainos Secures Ten Million Dollar Partnership Deal to Advance Key Drug Platform

San Diego, Thursday, 24 September 2026.
Biopharmaceutical firm Ainos signed a $10 million framework agreement with BioPhoenix, offloading expensive clinical trial costs for its drug platform while retaining core ownership and long-term commercial upside.